Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556788 · ClinicalTrials.gov registry record · Phase 3
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,212
- Enrollment target
NCT02556788 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 1,212 participants.
The verdict
NCT02556788, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,212 participants
- Enrollment target
Study Summary
Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Interventions
- DRUG Placebo Cream
- DRUG CD5789 (trifarotene) 50µg/g Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,212 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-05-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02556788
The ClinicalTrials.gov registry entry for NCT02556788 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Cream is the first listed.
NCT02556788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02556788 about?
NCT02556788 is a clinical study titled "Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris". Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
What is the current status of trial NCT02556788?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,212 participants. The study started on 2015-11. Estimated completion is 2017-05-12.
What interventions are being tested in trial NCT02556788?
The interventions under investigation include: Placebo Cream (DRUG), CD5789 (trifarotene) 50µg/g Cream (DRUG).
Who is sponsoring clinical trial NCT02556788?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.